aifollow.news
← TrendingLatest development Nov 17 21:39
STORY IN FOCUS

Isomorphic Labs raises $5B to advance drug candidates toward clinical trials

AI drug discovery company Isomorphic Labs has raised $5 billion in a Series C round as it seeks to take drug candidates to clinical trials. It plans to keep developing its drug-design engine and expand into more types of medicine. The company says its oncology and immunology programs have yielded positive preclinical results; those results do not establish how the candidates will perform in human trials.

1 developments2 reports2 sources

Event developments

Coverage of the same occurrence shares a node; subsequent developments have their own nodes.

Isomorphic Labs completes $5 billion Series C funding round

Alphabet's AI drug discovery company Isomorphic Labs announced a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital. It plans to use the funding to advance foundational simulation models, expand its internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.

View source reports · 2 sources · 2 reports
All reports · 2

By original publication time, with each report's bookmarks and feedback preserved.

TechCrunch AI Machine translation

Isomorphic Labs raises $5B to advance drug candidates toward clinical trials

AI drug discovery company Isomorphic Labs has raised $5 billion in a Series C round as it seeks to take drug candidates to clinical trials. It plans to keep developing its drug-design engine and expand into more types of medicine. The company says its oncology and immunology programs have yielded positive preclinical results; those results do not establish how the candidates will perform in human trials.

IT之家 科技新闻 Machine translation

Isomorphic Labs completes $5 billion Series C funding round

Alphabet's AI drug discovery company Isomorphic Labs announced a $5 billion Series C funding round, co-led by Greenoaks and Sequoia Capital. It plans to use the funding to advance foundational simulation models, expand its internal and partnered drug candidate programs, and build global AI-driven bioengineering infrastructure.